Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2

Ivermectin study #34 of 113 Meta Analysis

11/14 Late treatment study

Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed)
Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2

Source PDF Share Tweet

100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment.

Spoorthi et al., 11/14/2020, prospective, India, South Asia, peer-reviewed, 2 authors, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.

recovery time, 21.1% lower, relative time 0.79, p = 0.03, treatment 50, control 50.

hospitalization time, 15.5% lower, relative time 0.84, p = 0.01, treatment 50, control 50.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 113 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit